Fasenra Injection, Solution
Product Images NDC 0310-1730

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Fasenra (NDC 0310-1730). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure_1_saphnelo (Figure 1 Saphnelo)

Illustration showing two FASENRA prefilled syringes for subcutaneous injection. The 10 mg/0.5 mL syringe features a gray plunger rod and is packaged with a gray box labeled '10 mg/0.5 mL.' The 30 mg/mL syringe has a blue plunger rod and a pink-labeled box marked '30 mg/mL.' Both syringes display their respective dosage strengths.*

FDA Label Image

Figure_2_saphnelo (Figure 2 Saphnelo)

An exploded diagram of a syringe for an injection solution. Components labeled include the plunger head, plunger, needle guard activation clips, finger flange, syringe body, viewing window, label with expiration date, needle, and needle cover. The syringe is shown aligned horizontally with the needle cover detached to the right.*

FDA Label Image

Step 2 Needle Cover Image (Image 02)

An instructional illustration showing a hand holding a syringe with a needle cap being removed by another hand. The arrow indicates the direction to pull off the cap, demonstrating preparation of an injection.*

FDA Label Image

Step 3 (Image 03)

A black and white instructional illustration depicting a hand holding a syringe to administer a subcutaneous injection into the forearm, demonstrating the injection technique for the drug FASENRA (benralizumab) injection, solution.*

FDA Label Image

Step 4 (Image 04)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe into the fingertip, indicating the injection technique with a downward-pointing arrow.*

FDA Label Image

Step 5 (Image 05)

An instructional line drawing showing a hand holding a prefilled syringe, demonstrating the step of removing the cap by pulling it upward before injection.*

FDA Label Image

Figure 2 (Image 06)

A Kaplan-Meier curve chart depicting the probability of experiencing an exacerbation over 48 weeks comparing Benralizumab (Benra) 30 mg every 8 weeks to placebo. The chart shows cumulative probabilities on the y-axis and weeks on the x-axis, with two lines representing Benralizumab and placebo groups, including number at risk data and error bars at certain time points.*

FDA Label Image

Figure_3_change_from_baseline_fev1 (Image 07)

A line graph comparing change from baseline FEV1 (L) over 56 weeks between FASENRA (Benralizumab) 30 mg every 8 weeks and placebo in a high ICS dose group. The solid line represents FASENRA showing greater improvement, while the dashed line represents placebo. Error bars indicate variability, and sample sizes are listed at each interval.*

FDA Label Image

Figure_4_saphnelo (Figure 4 Saphnelo)

A Kaplan-Meier curve chart displaying the probability of experiencing HES flare over 24 weeks for Benralizumab versus placebo. The x-axis represents weeks, and the y-axis shows the probability percentage. The chart includes patient numbers at risk for each group at various time points.*

FDA Label Image

Your_fasenra_pen_before_use (Your Fasenra Pen Before Use)

An instructional diagram showing a FASENRA prefilled syringe before use. Key parts labeled include the cap, viewing window to observe the liquid medicine, the liquid medicine itself, and the label displaying the expiration date on the syringe barrel. The syringe is designed for subcutaneous injection of Benralizumab.*

FDA Label Image

Your_fasenra_pen_after_use (Your Fasenra Pen After Use)

An illustration labeled 'After Use' showing a prefilled injection pen with a green plunger visible inside and a needle guard covering the needle end. The pen is designed for subcutaneous injection, corresponding to FASENRA injection use.*

FDA Label Image

Ifu_step_1 (Ifu Step 1)

Illustration showing injection supplies related to FASENRA (benralizumab) subcutaneous injection. It depicts a FASENRA pen device, an alcohol wipe, cotton ball or gauze, a bandage, and a sharps container. A note states that alcohol wipes, cotton balls or gauze, bandages, and sharps containers are supplies not included in the product carton.*

FDA Label Image

Step_2_30_minute_clock (Step 2 30 Minute Clock)

An illustration of a stopwatch showing 30 minutes elapsed, with the right half filled in blue and the left half white. The number '30' and the word 'min' indicate a 30-minute time duration.*

FDA Label Image

Step_3_fasenra_pen_viewing_window (Step 3 Fasenra Pen Viewing Window)

An instructional illustration showing a hand holding a FASENRA (Benralizumab) injection pen, highlighting the device used for subcutaneous administration of the medication.*

FDA Label Image

Step_4_choose_the_injection_site (Step 4 Choose The Injection Site)

An anatomical illustration showing recommended subcutaneous injection sites for FASENRA (Benralizumab). Highlighted areas include the upper arms, abdomen (excluding a 2-inch area around the navel), and the front of the thighs. A label indicates the injection is intended for the caregiver site only.*

FDA Label Image

Step_5_clean_the_injection_site (Step 5 Clean The Injection Site)

An illustration showing a hand using a cloth or wipe to clean or disinfect a surface. The image likely represents part of the preparation process for administering an injection, emphasizing cleanliness before use.*

FDA Label Image

Step_6_pull_off_the_cap (Step 6 Pull Off The Cap)

Illustration showing hands removing the cap from a subcutaneous injection pen for FASENRA (benralizumab). The image depicts the proper step of detaching the pen cap prior to injection, with an arrow indicating the direction to pull the cap away from the pen.*

FDA Label Image

Step_7_a_position_the_pen_at_the_injection_site (Step 7 A Position The Pen At The Injection Site)

An instructional diagram showing hands holding a FASENRA prefilled syringe at a 90-degree angle to the skin, demonstrating the correct subcutaneous injection technique for administering the benralizumab injection solution.*

FDA Label Image

Step_7_b_position_press_down_firmly (Step 7 B Position Press Down Firmly)

Illustration showing a hand administering a subcutaneous injection using a pen injector device. The device is held vertically and positioned above the injection site on the forearm or hand, with the other hand stabilizing the skin.*

FDA Label Image

Step_7_c_hold_down_firmly_for_15_seconds (Step 7 C Hold Down Firmly For 15 Seconds)

An instructional illustration showing a hand holding a FASENRA injection device for subcutaneous injection. A stopwatch icon with "1 sec" indicates to hold the device in place for one second during administration.*

FDA Label Image

Step_7_d_lift_the_fasenra_pen_straight_up (Step 7 D Lift The Fasenra Pen Straight Up)

An instructional illustration showing a hand holding a pen-like injection device above a forearm, with an upward arrow indicating the motion to remove the cap or prepare for subcutaneous injection. This likely demonstrates part of the administration process for FASENRA (Benralizumab) injection solution.*

FDA Label Image

Step_8_check_the_viewing_window (Step 8 Check The Viewing Window)

An instructional illustration showing a close-up view of a FASENRA prefilled injection pen, held by a hand. The focus is on the dose window of the device, which displays a colored indicator bar, likely to show the status of the injection. The pen has a teal cap and purple components, consistent with FASENRA subcutaneous injection branding.*

FDA Label Image

Step_8_viewing_window_before_injection (Step 8 Viewing Window Before Injection)

An illustration showing a close-up of a device or component, possibly an injection syringe or pen, with a visible indicator window. The image focuses on the dosage indicator or scale within the device, relevant for subcutaneous injection administration.*

FDA Label Image

Step_8_viewing_window_after_injection (Step 8 Viewing Window After Injection)

The image shows a single-use prefilled syringe of FASENRA (benralizumab) injection. The syringe appears to be a 30 mg/mL strength in a clear barrel with a visible plunger and needle cover. No additional labeling or packaging details are visible.*

FDA Label Image

Step_9_check_the_injection_site (Step 9 Check The Injection Site)

An illustration showing a hand grasping a small, crumpled piece of cloth or tissue, positioned above a surface, likely demonstrating a step in a cleaning or preparation process related to injection administration.*

FDA Label Image

Step_10_sharps_container (Step 10 Sharps Container)

An instructional illustration showing a hand holding a prefilled syringe with a purple cap, positioned above a red sharps disposal container, demonstrating proper disposal of the syringe after use.*

FDA Label Image

Fasenra-30mg-carton-sales (Fasenra 30mg Carton Sales)

Fasenra 30 mg/mL injection label for subcutaneous use, featuring one single-dose prefilled syringe. Includes storage instructions to keep refrigerated between 36°F and 46°F (2°C - 8°C) in the original carton, with warnings not to shake, freeze, or expose to heat. Manufactured by AstraZeneca Pharmaceuticals LP.*

FDA Label Image

Fasenra-10mg-carton-sales (Fasenra 10mg Carton Sales)

Fasenra (benralizumab) Injection 10 mg/0.5 mL single-dose prefilled syringe for subcutaneous injection. The label instructs storing the prefilled syringe refrigerated at 36°F - 46°F (2°C - 8°C) in the original carton to protect from light, and advises not to shake, freeze, or expose to heat. Manufactured by AstraZeneca Pharmaceuticals LP.*

FDA Label Image

Fasenrapen-30mg_ml_single_dose_autoinjector_carton (Fasenrapen 30mg mL Single Dose Autoinjector Carton)

FASENRA Pen (benralizumab) Injection, 30 mg/mL, is a single-dose prefilled autoinjector for subcutaneous use. The label instructs storing the product refrigerated at 2°C to 8°C and warns against shaking, freezing, or heat exposure. The manufacturer is AstraZeneca Pharmaceuticals LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.